[Activity and efficacy of vinflunine in third line in patients with advanced urothelial carcinoma of the renal pelvis, progressing to immunotherapy]

Recenti Prog Med. 2018 Nov;109(11):547-550. doi: 10.1701/3031.30292.
[Article in Italian]

Abstract

The clinical case concerns a 72-years-old woman diagnosed with an urothelial carcinoma of the renal pelvis with hepatic and lymph node metastases. The disease was rapidly progressing to a first line of platinum-based chemotherapy and to a second line with immunotherapy; a clinical and instrumental benefit was then observed with vinflunine used as third line regimen.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
  • Carcinoma, Transitional Cell / pathology
  • Carcinoma, Transitional Cell / therapy*
  • Disease Progression
  • Female
  • Humans
  • Immunotherapy / methods*
  • Kidney Pelvis / pathology
  • Liver Neoplasms / secondary
  • Lymphatic Metastasis
  • Treatment Outcome
  • Urinary Bladder Neoplasms / pathology
  • Urinary Bladder Neoplasms / therapy*
  • Vinblastine / administration & dosage
  • Vinblastine / analogs & derivatives

Substances

  • vinflunine
  • Vinblastine